Printer Friendly

DONALD R. CONKLIN JOINS BOARD AT CYTOTHERAPEUTICS

 PROVIDENCE, R.I., June 8 /PRNewswire/ -- CytoTherapeutics, Inc. (NASDAQ: CTII) today announced the election of Donald R. Conklin, president of Schering-Plough Pharmaceuticals and executive vice president of Schering-Plough Corporation, to its board of directors.
 Conklin, who joined Schering-Plough in 1959, currently directs the company's U.S. and international pharmaceutical divisions, including Schering-Plough Animal Health and the Wesley-Jessen vision care company. While at Schering, Conklin has been instrumental in the development of Schering's biotechnology businesses and the development and commercialization of Intron A (alpha interferon), which is approved for the treatment of hepatitis B and C, Kaposi's sarcoma and hairy cell leukemia.
 "Mr. Conklin's extensive experience and keen understanding of the development and commercialization of biotechnology products will be extremely valuable as CytoTherapeutics develops and advances its own products toward commercialization," said Seth A. Rudnick, M.D., chairman of the board and chief executive officer of CytoTherapeutics.
 Prior to being named president in 1985, Conklin has held various marketing management positions in the U.S. and Europe. In 1977, he became vice president of marketing at Schering-Plough International; and, in 1980, he assumed responsibility for Latin American Operations. Following his service in Latin America, Conklin returned to the United States in 1983 as senior vice president, International Headquarters Operations.
 Conklin received his M.B.A. from Rutgers University in New Jersey, where he is a former lecturer for the M.B.A. program. He earned his B.A. degree with highest honors from Williams College. He also attended The Harvard Graduate School of Business Program for Management Development.
 CytoTherapeutics is a leader in the development and commercial application of implantable delivery systems for biologically active and gene therapy products for the treatment of central nervous system (CNS) diseases and other chronic disorders. The company's CNS products in development include its CereCRIB(tm) implant for the treatment of severe, chronic pain, and its NeuroCRIB(tm) implant for the treatment of Parkinson's disease. CytoTherapeutics is also developing its EndoCRIB(tm) implant for the treatment of Type I diabetes.
 -0- 6/8/93
 /CONTACT: Thomas G. Wiggans, chief operating officer, 401-272-3310, ext. 2152, or Elizabeth Razee, communications coordinator, 401-272-3310, ext. 2132, both of CytoTherapeutics/
 (CTII)


CO: CytoTherapeutics, Inc. ST: Rhode Island IN: MTC SU: PER

DJ -- NE015 -- 6622 06/08/93 14:23 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 8, 1993
Words:380
Previous Article:DANIEL I.C. WANG, PH.D., JOINS ALTUS SCIENTIFIC ADVISORY BOARD
Next Article:RAPP COLLINS MARCOA NAMES CO-MANAGING DIRECTORS
Topics:


Related Articles
THOMAS WIGGANS NAMED CHIEF OPERATING OFFICER OF CYTOTHERAPEUTICS
CYTOTHERAPEUTICS AND DRS. WEISS AND REYNOLDS TO INVESTIGATE USES OF NEURAL STEM CELLS TO TREAT NEURODEGENERATIVE DISORDERS
CYTOTHERAPEUTICS AND GENETIC THERAPY TO INVESTIGATE ENCAPSULATION OF FACTOR IX TO TREAT HEMOPHILIA B
DR. MARJORIE CHRISTIE APPOINTED DIRECTOR OF REGULATORY SCIENCES AT CYTOTHERAPEUTICS
FIRST HUMAN CLINICAL TRIAL BEGINS FOR CYTOTHERAPEUTICS' CERECRIB IMPLANT IN SWITZERLAND
CYTOTHERAPEUTICS ELECTS DANIEL GEFFKEN CHIEF FINANCIAL OFFICER
CYTOTHERAPEUTICS AND NEOCRIN COMPLETE AGREEMENT TO COMBINE DIABETES PROGRAMS
CYTOTHERAPEUTICS OBTAINS EXCLUSIVE, WORLDWIDE LICENSE TO NEURAL STEM CELLS FOR TRANSPLANTATION;
RESEARCHERS DEMONSTRATE CYTOTHERAPEUTICS' DELIVERY SYSTEM FOR NERVE GROWTH FACTOR PRESERVES NEURONS AFFECTED IN ALZHEIMER'S DISEASE
CytoTherapeutics and Cognetix Collaborate on Development of New Class of CNS Compounds

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters